Migraine Clinical Trial
— COBRAOfficial title:
ProspeCtive Observational Real-world Study of uBRogepant and Atogepant in Israel (COBRA)
| NCT number | NCT05827887 |
| Other study ID # | P24-078 |
| Secondary ID | |
| Status | Recruiting |
| Phase | |
| First received | |
| Last updated | |
| Start date | June 25, 2023 |
| Est. completion date | September 30, 2025 |
| Verified date | April 2024 |
| Source | AbbVie |
| Contact | Tal Nevo |
| Phone | +972(0)97909600 |
| tal.nevo[@]abbvie.com | |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational |
Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and sound. This study will evaluate how effective the use of ubrogepant and atogepant is in treating adult participants with migraine. Urogepant (Ubrelvy) and Atogepant (Qulipta) are approved drugs for treatment of migraine in adults in the US. Approximately 200 adult participants who are prescribed Ubrogepant or atogepant by their doctors will be enrolled in this study in Israel. Participants will receive ubrogepant oral tablets or atogepant oral tablets as prescribed by their physician. Participants will be followed for 90 days. There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.
| Status | Recruiting |
| Enrollment | 200 |
| Est. completion date | September 30, 2025 |
| Est. primary completion date | September 30, 2025 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility | Inclusion Criteria: - Confirmed diagnosis of migraine according to the ICHD-3 upon judgement of the treating physician - The patients should be naive to the designated treatment - Ability to fill an e-diary app Exclusion Criteria: - Patients who cannot be treated with UBRO or ATO according to the applicable approved label - Patients participating in a concurrent clinical interventional study or within the last 30 days - Patients who were previously treated with rimegepant will be excluded from the study |
| Country | Name | City | State |
|---|---|---|---|
| Israel | Assuta Ashdod Medical Center /ID# 260020 | Ashdod | HaDarom |
| Israel | Soroka University Medical Center /ID# 254551 | Be'er Sheva | HaDarom |
| Israel | Clalit HMO /ID# 257364 | Gani Tikva | |
| Israel | Hadassah Medical Center-Hebrew University /ID# 257352 | Jerusalem | |
| Israel | Shaare Zedek Medical Center /ID# 254169 | Jerusalem | Yerushalayim |
| Israel | Maccabi Healthcare Services /ID# 254171 | Kfar Saba | HaMerkaz |
| Israel | Meir Medical Center /ID# 254170 | Kfar Saba | HaMerkaz |
| Israel | The Chaim Sheba Medical Center /ID# 254550 | Ramat Gan | Tel-Aviv |
| Israel | ZIV Medical Center /ID# 257360 | Safed | HaTsafon |
| Israel | Tel Aviv Sourasky Medical Center /ID# 263089 | Tel Aviv | Tel-Aviv |
| Lead Sponsor | Collaborator |
|---|---|
| AbbVie |
Israel,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Ubrogepant (UBRO) Only: Percentage of Participants with Responder Status of "Extremely Satisfied" or "Satisfied" on a Single Item 7-Point Scale | The single item 7-point scale asks the question "Overall, how satisfied are you with Ubrelvy for treatment of your migraine?" to assess change in satisfaction of migraine treatment where 0 = extremely satisfied and 6 = extremely dissatisfied. | Baseline to Day 90 | |
| Primary | Atogepant (ATO) Only: Percentage of Participants with Responder Status of "Extremely Satisfied" or "Satisfied" on a Single Item 7-Point Scale | The single item 7-point scale asks the question "Overall, how satisfied are you with Qulipta for treatment of your migraine?" to assess change in satisfaction of migraine treatment where 0 = extremely satisfied, 1 = satisfied and 6 = extremely dissatisfied. | Baseline to Day 90 |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT06192173 -
Patent Foramen Ovale Closure in Migraine
|
||
| Completed |
NCT05525611 -
Cabergoline as a Preventive Treatment for Chronic Migraine
|
N/A | |
| Recruiting |
NCT03832998 -
Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine
|
Phase 3 | |
| Enrolling by invitation |
NCT04196933 -
Analysis of Vestibular Compensation Following Clinical Intervention for Vestibular Schwannoma
|
N/A | |
| Not yet recruiting |
NCT06428838 -
Eptinezumab as an Adjunct to Standard of Care for Migraine in an Acute Emergency Context
|
Phase 3 | |
| Completed |
NCT06304675 -
Manageable Environmental Factors in Migraine
|
||
| Completed |
NCT04084314 -
Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study
|
Phase 4 | |
| Recruiting |
NCT05517200 -
Pilot Study for a Machine Learning Test for Migraine
|
||
| Completed |
NCT04179474 -
Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine
|
Phase 1 | |
| Recruiting |
NCT04603976 -
Registry for Migraine - Clinical Core
|
Phase 4 | |
| Completed |
NCT03597529 -
CHOCOlate MeLatonin for AdolescenT MigrainE
|
Phase 2 | |
| Completed |
NCT04197349 -
Safety, Tolerability and Pharmacokinetics of ALD1910 in Healthy Men and Woman
|
Phase 1 | |
| Recruiting |
NCT05891808 -
miR-155 Expression in Episodic and Chronic Migraine
|
||
| Active, not recruiting |
NCT05064371 -
Long-Term Extension Study With Eptinezumab as Preventive Treatment in Participants With Migraine in Japan
|
Phase 3 | |
| Suspended |
NCT04069572 -
Vibratory Stimulation for the Treatment of Chronic Pain
|
N/A | |
| Not yet recruiting |
NCT04859374 -
Chronic Pain and Conditioned Pain Modulation After on Line-behavioral Approach
|
N/A | |
| Not yet recruiting |
NCT03083860 -
Evaluation of Migraine Management Mobile App Combined With Electrophysiological Measurements for Identification of Migraine Attack Risk and Beneficial Preventive Actions.
|
N/A | |
| Completed |
NCT02905227 -
A Study of the Pulmonary Safety and Pharmacokinetics of Zolmitriptan Inhalation Powder
|
Phase 1 | |
| Enrolling by invitation |
NCT02532023 -
The Combined Effects of omega3 Fatty Acids and Curcumin Supplementation on Inflammatory and Endothelial Factors in Migraine Patients
|
Phase 4 | |
| Completed |
NCT02108678 -
One-Day Intervention for Depression and Impairment in Migraine Patients
|
N/A |